Sarcoma Clinical Trials

Protocol No.PITitle
OSU-13097Tony Bekaii-SaabA Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of AMG 337 in Adult Subjects with Advanced Solid Tumors
OSU-9952Albert de la ChapelleStorage of DNA/RNA for the Discovery of Genes Involved in Cancer Predisposition - A Tissue Collection Study
OSU-12067Erin MacraeDecision Impact Analysis of Foundation Medicine's Next Generation Sequencing Test in Advanced Solid Tumor Malignancies
OSU-14077Erin MacraeA Phase 1 Dose Escalation Study Evaluating the Safety and Tolerability of PF-06650808 in Patients with Advanced Solid Tumors
OSU-10149Electra PaskettAppalachia Community Cancer Network II Focus Groups
OSU-14032Raphael PollockEstablishing Cell Lines and Examining Tumor and Peripheral Blood Biological Markers from Human Sarcoma
OSU-10025Stephen PovoskiRestrospective Evaluation of Patients Undergoing Surgery and Same-Day Intravenous Administration of 18F-FDG
OSU-13053Sameek RoychowdhuryPrecision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
OSU-14054Sameek RoychowdhuryModular phase II study to link targeted therapy to patients with pathway activated tumors:Module 3 - MEK162 for patients with RAS/RAF/MEK activated tumors
OSU-10119Thomas ScharschmidtEstablishing Sarcoma Xenografts
OSU-12066Manisha ShahA Phase I Trial of GSK2118436 (BRAFi) and Pazopanib in Patients with BRAF-Mutated Advanced Malignant Tumors
COG-NRGARST1321Meng WelliverPazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754, IND# 118613)
OSU-13211Robert WesolowskiAn Open-Label, First-in-Human Study of the Safety, Tolerability, and Pharmacokinetics of VX-970 in Combination With Cytotoxic Chemotherapy in Subjects With Advanced Solid Tumors
AMC-087Christina WuPhase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 460 W. 10th Avenue, Columbus, OH 43210 Phone: 1-800-293-5066 | Email: